The treatment regimen in severe Covid-19 patients has several types of therapies. However, there is uncertainty about which therapies are more effective in the covid-19 weight category. In June 2020, the study was conducted with keyword search [REMDESIVIR] [RUXOLITINIB] [COVID19] in 2010-2020 using PUBMED.gov. This study used rct (randomization controller trial) method with the theme: the comparison of the effectiveness use of Remdesivir with Ruxolitinib on Covid-19. From the results of the analysis using forest plot obtained, there was a significant difference in the administration of Remdesivir therapy with Ruxolitinib on the improvement from covid-19 on day 7 (1.26 CI 95% 0.41 to 3.86) and day 14 (RR 1.26 CI 95% 0.41 to 3.86). Ruxolitinib therapy is more effective than Remdesivir applied for Covid-19 patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.